[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-aging":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,55,95,137,161,189,220,241,264,289,314],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100644520","early-phase-1-piezo-101-first-in-human-safety-and-proof-of-concept-study-100644520",false,"NCT07671027","PIEZO-101 First-in-Human Safety and Proof-of-Concept Study","An Open-Label, Within Participant-Controlled, First-in-Human (FIH) Study to Explore the Safety, Tolerability, and Pharmacodynamic Effects of PIEZO-101, an Investigational Plasmid DNA Biostimulator Delivered by Intradermal Electroporation to the Knee and Décolleté Regions in Healthy Adult Female Participants","Inclusion Criteria (Participants must meet ALL of the following criteria to be eligible for enrollment):\n\n1. Healthy female adults aged 40-65 years\n2. Fitzpatrick skin phototype score I-IV\n3. Visible signs of skin laxity, wrinkling, or crepiness in the knee area, confirmed by photographic documentation reviewed by at least two independent assessors\n4. Visible signs of wrinkling or crepiness in the décolleté area suitable for standardized photography, free of tattoos, significant scarring, or confounding skin conditions in the photography field, confirmed by photographic documentation reviewed by at least two independent assessors\n5. Willingness to undergo all protocol-required skin punch biopsies (four at Day 7 and four at Day 35) from the knee area\n6. Willingness to abstain from other aesthetic or dermatologic treatments in the knee and décolleté areas during the study\n7. For women of childbearing potential (WOCBP): commitment to use a highly effective method of contraception (combined hormonal contraception, progestogen-only contraception, intrauterine device or hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence) from the Screening Visit through the Day 90 End-of-Study visit. Postmenopausal status, defined as ≥12 months of natural amenorrhea, is not considered childbearing potential.\n8. Negative serum β-hCG pregnancy test at the Screening Visit (Visit 1) and negative urine pregnancy test at the treatment visits (Visit 2 and Visit 6) prior to dose for participants of child-bearing potential\n9. Willing and able to comply with all scheduled visits (10 study site visits), treatment plan, and study procedures for the full 90-day study duration\n10. Able to understand and willing to sign a written informed consent document.\n\nExclusion Criteria (Participants must meet NONE of the following criteria to be eligible for enrollment):\n\n1. History of keloid or hypertrophic scarring\n2. Known allergy or hypersensitivity to any antibiotic\n3. Known hypersensitivity to lidocaine, prilocaine, or any component of the topical anesthetic preparation\n4. Active dermatologic conditions or infections (such as psoriasis, eczema, active acne, or dermatitis) in the knee or décolleté treatment areas\n5. History of knee surgery or significant scarring in the knee treatment area; history of breast augmentation, reduction, or surgery resulting in scarring in the décolleté treatment area\n6. Use of systemic corticosteroids, immunosuppressants, or medications affecting wound healing within 30 days of Day 0\n7. Known autoimmune disease or immunodeficiency\n8. Pregnancy or breastfeeding\n9. Participation in another investigational study within 30 days of Day 0\n10. Known allergy to metals such as stainless steel\n11. Prior gene therapy of any kind (for clarity, prior receipt of RNA and DNA vaccines is not exclusionary)\n12. Implanted electronic device (e.g., cardiac pacemaker, defibrillator, neurostimulator)\n13. Any aesthetic procedure (injectable, energy-based device, laser, filler, biostimulator, chemical peel, topical prescription product) in the knee or décolleté areas within 6 months of screening\n14. Tattoos, permanent makeup, or scarring in the knee or décolleté treatment areas that could interfere with clinical or photographic assessments\n15. History of any malignancy within 5 years prior to screening, except adequately treated basal cell or squamous cell carcinoma of the skin outside the treatment areas\n16. Any condition that, in the opinion of the PI, would compromise participant safety or study integrity.",true,"FEMALE","40 Years","65 Years",{"count":21,"type":22},8,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The aim of this first-in-human clinical study is to explore the safety, tolerability, pharmacodynamics, and exploratory efficacy of PIEZO-101, an investigational plasmid DNA biostimulator that aims to restore expression of key proteins in the skin for extracellular matrix rejuvenation. PIEZO-101 is administered using an intradermal injection followed by localized electroporation using the investigational device Piezopen. This clinical trial will study safety and tolerability, pharmacodynamics using biopsies from the left knee, and exploratory efficacy using photography on the décolleté. Up to 8 participants may be enrolled to ensure 6 evaluable participants complete the study.",[28,29,30,31,32],"Skin Aging","Wrinkles in Decolletage","Wrinkles in Left Knee","Left Knee Skin Laxity","Décolleté Wrinkles",[34,35,36,37,38,39,40,41,42],"Skin aging","Decolette wrinkles","Knee skin laxity","Intradermal electroporation","Plasmid DNA","Biostimulator","Extracellular matrix regeneration","Skin rejuvenation","First-in-human","NOT_YET_RECRUITING","2026-06-22",{"date":46,"type":47},"2026-06-26","ACTUAL",{"date":49,"type":22},"2026-09",{"date":51,"type":22},"2027-08",{"name":53,"class":54},"Piezo Therapeutics, Inc.","INDUSTRY",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":16,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100644275","effect-of-single-facial-acupuncture-on-dermal-structure-and-appearance-satisfaction-100644275","NCT07664280","Effect of Single Facial Acupuncture on Dermal Structure and Appearance Satisfaction","Effects of Single-Session Facial Acupuncture on Dermal Structure and Aesthetic Satisfaction: A Randomized Controlled Trial Combining High-Frequency Ultrasound and Patient-Reported Outcomes","FRA","Inclusion Criteria:\n\n* Adults aged 30 to 60 years old. Individuals concerned about facial aging issues.\n* Individuals without severe chronic diseases.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with coagulation disorders.\n* Individuals with a keloid constitution or tendency for abnormal scarring.\n* Individuals with acute or chronic facial hemiplegia\u002Fparalysis of any cause.\n* Individuals who have undergone facial cosmetic surgery or cosmetic injections within the past 6 months.\n* Individuals currently taking anticoagulant medications.\n* Individuals with active skin infections.\n* Individuals with a history of severe allergies.\n* Individuals otherwise deemed unsuitable for facial acupuncture by the investigators.","ALL","30 Years","60 Years",{"count":67,"type":22},60,[69],"NA","This study aims to investigate the effects of a single session of facial rejuvenation acupuncture on skin structure and personal satisfaction with facial appearance. As facial aging involves complex changes in muscles, skin, and soft tissues, facial acupuncture is considered a potential minimally invasive treatment to help restore balance and promote tissue repair.\n\nResearchers will enroll 60 healthy adults aged 30 to 60 who are concerned about facial aging. Participants will be randomly assigned to either an immediate intervention group or a waitlist control group. The intervention group will receive one session of facial acupuncture at the start of the study. The control group will continue their normal daily skincare routine for 6 weeks, after which they will receive the same single acupuncture treatment.\n\nAll participants will be monitored weekly for 6 weeks. The research team will use non-invasive tools, including high-frequency skin ultrasound, 3D facial scanning, and a digital complexion analysis system, to objectively measure changes in skin thickness, facial volume, and wrinkles. Participants will also complete questionnaires at various time points to share their satisfaction with their appearance, self-confidence, and quality of life.",[72,73,28],"Facial Aging","Wrinkles",[75,76,77,78,79,80,81,82],"Facial Rejuvenation Acupuncture","Acupuncture Therapy","Dermal Thickness","Skin Rejuvenation","High-Frequency Ultrasound","3D Facial Scanning","Facial Contouring","Patient Satisfaction","RECRUITING","2026-06-17",{"date":86,"type":47},"2026-06-24",{"date":88,"type":47},"2026-06-11",{"date":90,"type":22},"2027-08-31",{"name":92,"class":93},"Far Eastern Memorial Hospital","OTHER",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":16,"sex":63,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":94},"100643775","effectiveness-and-safety-of-cellbooster-shape-in-healthy-subjects-100643775","NCT07636512","Effectiveness and Safety of Cellbooster Shape in Healthy Subjects","A Prospective, Open-label Study on the Effectiveness and Safety of Cellbooster® Shape (Stabilized Booster Complex Using CHAC Technology) on Healthy Subjects.","Inclusion Criteria:\n\n1. Healthy subject.\n2. Sex: male and female.\n3. Phototype II to IV.\n4. Age: from 35 years old.\n5. Subject with light to moderate signs of cutaneous ageing of the face.\n6. Subject with a skin hydration rate on cheekbones \\\u003C 60 UA, measured with Corneometer®.\n7. Subject with light to moderate localized submental (double chin) and\u002For malar puffiness (at least 35 in each indication).\n8. Subject looking for an anti-age improvement using an aesthetic procedure.\n9. Subject willing to abstain from other facial aesthetic procedure in the full face through the entire study duration.\n10. Subject having given their free, express, and informed consent.\n11. Subject psychologically able to understand the information related to the study, and to give their written informed consent.\n12. Subject registered to a social security scheme.\n13. Female of childbearing potential must use a medically accepted contraceptive method since at least 12 weeks before the beginning of the study and throughout the study.\n14. Female subjects of childbearing potential must have a negative pregnancy test at the inclusion.\n\nExclusion Criteria:\n\nIn terms of population\n\n1. Pregnant or nursing woman or planning a pregnancy during the study.\n2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.\n3. Subject in a social or sanitary establishment.\n4. Subject participating to another research on human beings or being in an exclusion period for a previous study.\n5. Subject having received a total of 6.000 euros as compensation for their participation in research involving human beings in the last 12 months, including their participation in the present study.\n6. Intensive exposure to sunlight or UV-rays within the previous month and\u002For planning to do so during the study.\n\nIn terms of associated pathology 17. Subject with ongoing uncontrolled depression and\u002For recently recovered (\\\u003C6 months) or psychiatric disorders or any other disorder that may pose a health risk to the subject in the study and\u002For may have an impact on the study assessments, at the investigator appreciation. 18. Subject with severe, ongoing and uncontrolled diseases such as malignancy or history of malignancy, type I diabetes, liver failure, renal failure, lung\u002Fheart disease, neoplasia, malignant blood disease, tumor, HIV, or other major disease (e.g., systemic fungal infection). 19. Subject with recurrent porphyria, coronary insufficiency, ventricular rhythm disorders, severe hypertension, obstructive cardiomyopathy, hyperthyroidism.\n\n20\\. Subject with any skin or systemic disease (acute and\u002For chronic) likely to interfere with the measured parameters or to put the subject to an undue risk.\n\n21\\. Subject with known history of or suffering from autoimmune disease and\u002For immune deficiency.\n\n22\\. Subject with current cutaneous inflammatory or infectious processes (e.g., acne, herpes, mycosis, papilloma, chronic eczema, atopic dermatitis \\&), abscess, unhealed wound, or a cancerous or precancerous lesion on the face.\n\n23\\. Subject with multiple severe allergies history, anaphylactic shock history, quincke's oedema, evolutive allergic pathologies.\n\n24\\. Subject having history of allergy or hypersensitivity to one of the components of the tested device.\n\n25\\. Subject having history of hypersensitivity to the antiseptic solution, to lidocaine and\u002For prilocaine or local anesthetics of amide type or one of the excipients of EMLA 5% cream.\n\n26\\. Subject predisposed to keloids or hypertrophic scarring. 27. Subject with coagulation and\u002For homeostasis disorders. 28. Subject with pigmentation disorders (vitiligo, melasma).\n\nRelated to previous or ongoing treatment 29. Subject under anti-coagulant treatment (such as aspirin, nonsteroidal anti-inflammatory drugs) or treatment liable to interfere with the healing process or hemostasis, during the previous month before injection and during the study.\n\n30\\. Subject receiving any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject to undue risk.\n\n31\\. Subject having received a COVID vaccination within the past 3 weeks prior to the injection or planning to receive one within the 2 weeks following injection.\n\n32\\. Subject undergoing a topical (on the face) or systemic treatment:\n\n* anti-inflammatory medication during the previous 2 weeks and during the study.\n* anti-histaminics during the previous 7 days.\n* immunosuppressors and\u002For corticoids during the 4 previous weeks and during the study\n* retinoids during the 6 previous months and during the study","35 Years",{"count":104,"type":22},50,[69],"SUISSELLE has developed a CE marketed (2021) HA-based superficial epidermis\u002Fdermis injection filler and skinbooster product, Cellbooster® Shape (CBS). CBS is produced using patented CHAC Technology. It consists of non-crosslinked HA with L-Carnitine and vitamin C. The device is particularly designed for reducing local puffiness by improving microcirculation and hydration.\n\nThe current post-market clinical investigation is designed to evaluate the efficacy and safety of CBS. For this purpose, healthy subjects with signs of skin aging in the face will receive a 3-session treatment and will be followed-up over 70 days after the initial injection session.\n\nSeveral objective measurements of skin quality will be performed with different instruments allowing to assess skin volume, skin elasticity, skin hydration, and skin microcirculation. Subjective clinical improvement will be evaluated, as well as subject and investigator satisfactions.\n\nThe safety of the injections will be assessed by collecting the Injection Site Reactions (ISRs) and Adverse Events (AEs).",[28],[34,109,110,111,112,113,114,115,116,117,118,119,120,121,41,122,123,124,125,126,127],"Facial aging","Hyaluronic acid","Dermal injection","Skin hydration","Skin elasticity","Microcirculation","Facial puffiness","Global Aesthetic Improvement Scale","Subcutaneous injection","Patient satisfaction","Submental","Periocular","Nasolabial fold","skin booster","Double chin","Cellbooster","Cellbooster Shape","Fat pad","Malar fat pad","2026-06-03",{"date":130,"type":47},"2026-06-09",{"date":132,"type":47},"2026-03-31",{"date":134,"type":22},"2026-08-25",{"name":136,"class":54},"Suisselle",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":16,"sex":63,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":94},"100619271","phase-4-randomized-trial-of-combination-treatment-with-sofwave-and-sculptra-100619271","NCT07342452","Randomized Trial of Combination Treatment With Sofwave and Sculptra","A Prospective Pilot Study Comparing Immediate Combination Versus Sequential Treatment Using Injectable Poly-L-lactic Acid and Synchronous Ultrasound Parallel Beam Technology","Inclusion Criteria:\n\n1. Male and female subjects ≥ 40 years old\n2. Able to provide informed consent\n3. Baseline level of upper arm skin flaccidity and volume loss as defined as type III or greater on the Arm Visual Analog Scale (Arm VAS) for aging\n\nExclusion Criteria:\n\n* Prior treatment to the arms with a biostimulatory agent, energy-based device, or skin-tightening device within the past year.\n* History of dermabrasion or deep peels involving the upper arms within the past year.\n* History of prior surgery involving the upper arms.\n* History of prior fat reduction procedures within the upper arms.\n* History of keloids, hypertrophic scarring, or connective tissue disorders.\n* Active dermatologic condition involving the treatment site.\n* Active systemic or local infection or wounds at treatment site.\n* History of lymphatic drainage problems involving the upper arms.\n* Excessive subcutaneous fat in the upper arms as judged per the investigator.\n* Use of immunosuppressive or anticoagulant\u002Fantiplatelet medications.\n* Uncontrolled medical conditions interfering with wound healing or impacting bleeding.\n* Use of weight loss medications or supplements within the month before the baseline visit.\n* BMI ≥ 30 kg\u002Fm².\n* Non-stable weight (\\>5% change) during the month prior to enrollment.\n* Uncontrolled or current hormonal imbalance, including thyroid, pituitary, or androgen-related disorders.\n* History of malignancy during the past 5 years.\n* Implanted devices, such as pacemaker or defibrillator.\n* Active pregnancy, recent pregnancy within the past 3 months, planning to become pregnant during the study period, and\u002For breastfeeding.\n* History of heavy smoking during the past 10 years.\n* History of substance abuse, mental dysfunction, or other factors limiting ability to cooperate with study procedures.\n* Known allergy to any topical anesthetics or PLLA.\n* Presence of metal implants or metallic foreign bodies within the treatment area (upper arms).",{"count":145,"type":22},13,[147],"PHASE4","Evaluation of treatment on the upper arm with Sculptra and Sofwave on the same day versus Sofwave followed by Sculptra 1 month later.",[28],[151],"Laxity, Skin, Arm, Sofwave, Sculptra","2026-05-11",{"date":154,"type":47},"2026-05-12",{"date":156,"type":22},"2026-07",{"date":158,"type":22},"2027-04-01",{"name":160,"class":93},"Massachusetts General Hospital",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":16,"sex":63,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100559667","phase-1-preliminary-evaluation-of-the-safety-and-tolerability-of-spot-mrna01-subcutaneously-administered-in-healthy-subjects-100559667","NCT06567119","Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.","Inclusion Criteria:\n\nAged 18 to 75 years inclusive at the time of informed consent.\n\nExclusion Criteria:\n\n1. Any transient or chronic skin condition, disorder, or infection within 20 cm of the target areas before treatment that, in the opinion of the investigator, may confound study results.\n2. History of laser treatment or chemical peels or any cosmetic anti-aging treatments to the target areas within six months of the study treatment.\n3. History of surgical procedures to target areas, including removal of benign or malignant skin cancers that, in the opinion of the investigator, may confound study results.\n4. Participant with a history of heavy smoking, alcohol or drug abuse or steroid treatment.\n5. Pregnant or breast-feeding females.\n6. History of anaphylaxis or allergic reactions to any constituent of the study product and\u002For local anesthetics, and\u002For history of severe abnormal drug reaction.\n7. Those who have participated in clinical trials of other investigational drugs within 3 months before the study treatment.\n8. Those who are not suitable for subcutaneous injection and biopsy.\n9. Any condition that the investigator or primary physician believes may not be appropriate for participating the study.","18 Years","75 Years",{"count":171,"type":22},10,[173],"PHASE1","This is a first-in-human, randomized, double-blind, placebo-controlled clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 injection in healthy adult volunteers.",[28],[177,178,179],"SPOT-mRNA01","COL1A1 mRNA","EVs","2026-04-21",{"date":182,"type":47},"2026-04-23",{"date":184,"type":22},"2027-01-11",{"date":186,"type":22},"2029-02-12",{"name":188,"class":54},"SIPO Biotechnology Co. Ltd.",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":16,"sex":63,"minAge":168,"maxAge":19,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100628846","phase-3-objective-evaluation-of-intradermal-msc-derived-exosome-therapy-on-facial-skin-quality-100628846","NCT07466953","Objective Evaluation of Intradermal MSC-Derived Exosome Therapy on Facial Skin Quality","Objective Analysis of the Effects of Intradermally Administered Mesenchymal Stem Cell-Derived Suspended Exosome Therapy on Facial Skin Quality Using a Standardized Imaging System","Inclusion Criteria:\n\n* • Adults aged 18 to 65 years\n\n  * Individuals presenting facial skin aging signs\n  * Willingness to undergo three intradermal treatment sessions\n  * Ability to comply with study visits and follow-up assessments\n  * Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n\n  * Active skin infection, inflammatory skin disease, or open wounds in the treatment area\n  * History of allergic reactions to injectable dermatologic treatments\n  * Use of systemic or topical retinoids within the past 6 months\n  * Receipt of facial cosmetic procedures (laser treatment, fillers, botulinum toxin, PRP, or similar treatments) within the past 6 months\n  * Presence of autoimmune disease or immunosuppressive conditions\n  * Active malignancy or ongoing cancer treatment\n  * Participation in another clinical study within the past 3 months",{"count":197,"type":22},30,[199],"PHASE3","This study aims to evaluate the potential effects of mesenchymal stem cell-derived suspended exosome therapy on facial skin quality using objective imaging analysis. Thirty adult participants will receive intradermal exosome applications in three treatment sessions performed at one-month intervals. Facial skin analysis will be conducted using the VISIA imaging system before each treatment session and six months after the final treatment. The study will examine changes in multiple facial skin characteristics including wrinkles, pigmentation, skin texture, pores, UV spots, red areas, brown spots, and porphyrins to determine whether exosome therapy may improve overall facial skin quality.",[28,72,202],"Skin Quality",[204,205,206,207,208,209,210],"Exosome Therapy","Mesenchymal Stem Cell Exosomes","Facial Rejuvenation","Skin Imaging","VISIA Skin Analysis","Skin Aging Treatment","Regenerative Dermatology","2026-03-08",{"date":213,"type":47},"2026-03-12",{"date":215,"type":22},"2026-04-01",{"date":217,"type":22},"2026-12-31",{"name":219,"class":93},"Mert Ersan",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":65,"enrollmentInfo":227,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100602210","menopausal-impact-on-skin-aging-among-egyptian-women-100602210","NCT07120542","Menopausal Impact on Skin Aging Among Egyptian Women","Menopausal Impact on Skin Aging Among Egyptian Women: a Comparative Cross-sectional Study","Inclusion Criteria:\n\n* Females aged 40 to 60 years\n* Egyptian nationality or residency\n* Ability to provide informed consent\n* Classified as either:\n\n  * Premenopausal (still menstruating regularly)\n  * Postmenopausal (no menstruation for ≥12 months)\n\nExclusion Criteria:\n\n* Menopausal transition (Perimenopausal women\n* Menopause induced by hysterectomy\n* History of hormone therapy in the past 6 months\n* Active dermatological conditions affecting the face (e.g. eczema, psoriasis)\n* Use of anti-aging skin treatments (e.g. laser, fillers, retinoids)\n* Severe chronic illnesses that may affect skin condition",{"count":228,"type":22},500,"OBSERVATIONAL","The goal of this study is to understand how menopause affects skin aging in Egyptian women between the ages of 40 and 60.\n\nThe main question the study wants to answer is:\n\nDoes menopause cause any changes in how the skin ages?\n\nTo find out, the participants will be divided into two groups based on their menstrual history:\n\n* Women who have not yet gone through menopause (premenopausal)\n* Women who have already gone through menopause (postmenopausal) A researcher will examine the skin of women in both groups to look for signs of aging. Then, the results will be compared to see if there are any differences between the two groups.",[28],"2025-08-12",{"date":234,"type":47},"2025-08-13",{"date":236,"type":22},"2025-11-01",{"date":238,"type":22},"2027-11",{"name":240,"class":93},"Sohag University",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":16,"sex":17,"minAge":102,"maxAge":65,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100584636","a-clinical-study-on-pre-operative-intervention-with-products-during-aesthetic-medicine-100584636","NCT06891924","A Clinical Study on Pre-operative Intervention With Products During Aesthetic Medicine","Clinical Study on Pre-operative Intervention With Products to Mitigate Skin Discomfort During Aesthetic Medicine","Inclusion Criteria:\n\n* health females aged 35-60;\n* subjects with rough dark, loose fine lines;\n* no history of cosmetic allergies;\n* subjects are willing to use the test serum on split-face for 28 days;\n* subjects are willing to suffer the Fotona 4D treatment (Frac3 and Piano modes) on the face;\n* subjects are willing to use the basic skincare products for 28 days, and acceptable for split-face use of the test products or the control product for 14 days;\n* written informed consent and portrait right consent were obtained from all participants before study entry.\n\nExclusion Criteria:\n\n* anyone who is pregnant, nursing an infant, or planning a pregnancy during the study;\n* subjects with known allergies or sensitivities to the ingredients in any of the study products;\n* any symptoms of facial flushing, erythema, papules, desquamation, or edema as evaluated by a physician prior to initial screening or Fotona4D Pro treatment;\n* unhealed skin lesions;\n* participated in any other clinical trial within one month;\n* received facial skin treatments including but not limited to lasers, chemical peels, and dermal fillers within one month;\n* taken\u002Finjected anti-allergy medication in the past one month;\n* participants in other clinical trials at the same time;\n* any subjects that the investigator considers ineligible.",{"count":249,"type":22},33,[69],"This clinical trial aims to evaluate whether a 14-day pre-operative application of the test product (containing MLYAAT-1002®, a proprietary anti-aging complex) can mitigate skin discomfort during Fotona 4D laser therapy (Frac3 and Piano modes) by comparing clinical evaluation, skin attributes measurement and subject self-assessment.",[28,253,254],"Skin Condition","Skin Manifestations","2025-03-26",{"date":257,"type":47},"2025-04-01",{"date":259,"type":22},"2025-03-25",{"date":261,"type":22},"2025-06-01",{"name":263,"class":54},"Botanee Group Co., Ltd.",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":16,"sex":17,"minAge":271,"maxAge":19,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":94},"100571979","biometrical-evaluation-of-the-efficacy-of-a-food-supplement-versus-placebo-100571979","NCT06727292","Biometrical Evaluation of the Efficacy of a Food Supplement Versus Placebo","FB_BfW","Inclusion Criteria:\n\n* Phototype: I to IV;\n* Subjects with normal to dry skin;\n* Subjects with healthy skin on the study area;\n* Non-smokers;\n* Has normal nutritional habits (not vegetarian\u002Fvegan);\n* Is not pregnant or lactating;\n* Has a BMI of 18 - 33 kg\u002Fm2;\n* Is willing to refrain from taking dietary supplements (at best not at all, in any case not during the last month before study start);\n* Willing not to use any oral products or any nutritional supplementation aiming at improving skin status during the course of the study;\n* No history of malabsorption diseases, liver diseases, or diseases of the lipid metabolism;\n* Uses no medication, which may interact with the study product\n\nExclusion Criteria:\n\n* For women: pregnant or nursing woman or woman planning to get pregnant during the study;\n* Cutaneous pathology on the study zone (eczema, etc.);\n* Subject with make-up on the day of the visit at the laboratory;\n* Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the efficacy of the study product:\n\n  * change in anti-wrinkle, smoothing and\u002For firming topical products within previous week on the studied zones,\n  * non-invasive procedures within previous month on the studied zones,\n  * intake of food supplement acting on skin within the three previous months,\n  * invasive procedures:\n\n    * deep chemical peeling within previous 3 months on the studied zones,\n    * mesotherapy, dermapen, laser within previous 6 months on the studied zones,\n    * botox and\u002For hyaluronic acid injections within previous 12 months on the studied zones;\n* Intake of vitamin substances and diets comprising a change of normal eating habits;\n* Known allergy to one or several investigational product´s ingredients;\n* Participation in a nutritional study within the last 30 days;\n* Surgical or internal diseases e.g. a metabolic or endocrine disease that may affect the outcome of the study (e.g. diabetes, liver diseases, kidney disorders) or having a history of medical or surgical events that may significantly affect the study outcome including any cardiovascular disease, skin disease, hypertension (\\>140\u002F90 mm Hg in three repeated measurements).","45 Years",{"count":273,"type":22},66,[69],"The purpose of this clinical trial is to evaluate whether nutritional supplementation over a 2-month period improves skin physiological parameters. This is a national, single-center, double-blind, randomized pilot study.\n\nThe study will be conducted using a supplement and a placebo, the safety of which has been assured by the sponsor.\n\nParticipants will:\n\n* Take a food supplement or a placebo once daily for 2 months\n* Visit the study center at beginning, after 28 days and after 56 days of supplementation.\n* Keep a diary of their skin status and tolerability\n\nThe secondary objective is to evaluate product characteristics and performance during normal use in healthy subjects.",[28,277,253],"Hair Condition",[279],"improvements of skin physiological parameters","2024-12-06",{"date":282,"type":47},"2024-12-10",{"date":284,"type":47},"2024-10-14",{"date":286,"type":22},"2025-05-30",{"name":288,"class":54},"Finzelberg GmbH & Co. KG",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":16,"sex":63,"minAge":102,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":313},"100571353","evaluation-of-the-safety-and-efficacy-of-profhilo-structura-100571353","NCT06719154","Evaluation of the Safety and Efficacy of Profhilo® Structura","Prospective, Multicentric, Controlled, Double Arm Clinical Investigation to Evaluate the Safety and Efficacy of Profhilo® Structura for Face Adipose Tissue Restoration","Inclusion Criteria:\n\n1. Healthy subjects\n2. Male and Female subjects.\n3. Age : between 35 and 55 year\n4. Subject having given freely and expressly his\u002Fher informed consent obtained according to ISO 14155:2020 and Good Clinical Practice (GCP)\n5. Only for treated group: Subject seeking aesthetic improvement for a corrective\u002Ffilling action of natural and induced skin depressions\n6. Women of childbearing potential must have a negative urine pregnancy test result at inclusion visit and must use a reliable method of contraception since at least 12 weeks and throughout the study.\n7. Subject psychologically able to understand the information related to the investigation including possible risks and side effects.\n8. Subject able to cooperate with the Investigator and to comply with the requirements of the entire investigation (including ability to attend all the planned investigation visits according to the time limits), based on investigator's judgement.\n9. Subject agreeing to keep their usual cleansing \u002F care products during the whole study period.\n10. Subject agreeing to apply a SPF50 cream during the whole study period.\n\nExclusion Criteria:\n\nIn terms of population\n\n1. Pregnant or breastfeeding woman or planning a pregnancy during the study.\n2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.\n3. Subject in a social or sanitary establishment.\n4. Subject enrolled in another study or whose non-enrollment period is not over.\n5. For France only: subject having received a total of 6.000 euros as compensations for their participation in the present study.\n6. Subject disagrees to keep a stable weight during the study (BMI variation ± 1)\n7. Subject with high expectations for the treatment effect.\n\n   In terms of associated pathology\n8. Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results and\u002For subject safety\n9. Subject with known history of or suffering from autoimmune disease and\u002For immune deficiency\n10. Subject suffering from active disease such as inflammation, infection, tumour, inflammatory and\u002For infectious cutaneous disorders (herpes, acne, rosacea, porphyria…) in the 6 months before screening visit\n11. Subject with a history of streptococcal disease or an active streptococcus infection\n12. Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders.\n13. Subject predisposed to keloids or hypertrophic scarring or having healing disorders\n14. Subject having history of severe allergy or anaphylactic shock including known risk of hypersensitivity to one of the components of the composition of the investigational device and to antiseptic solution related to previous or current treatment.\n15. Subjects with scar, mole, hair or local skin infection (including viral, bacterial, and fungal); skin granulomas; scar constitution; immune system disorders; presence of active or progressive skin disorders or skin diseases with isomorphic response in the treatment area, such as acute eczema, flat wart, lichen planus, psoriasis vulgaris, etc…\n16. Patients with psychiatric disorders or emotional instability.\n\n    In terms of previous or ongoing treatment or procedure\n17. Any medication which may interfere, at the interpretation of the investigator, with the study objectives.\n18. Subject having undergone tooth extraction or dental implant procedure within the past 6 weeks or plans to undergo these procedures during the study.\n19. Subject having received facial or cervico-facial lifting in the past 24 months or plans to undergo these procedures during the study.\n20. Subject having received treatment with a laser, ultrasound or radiofrequency treatment, a dermabrasion, a surgery, a chemical peeling or any other procedure based on active dermal response on the face within the past 6 months or who plans to undergo any of these procedures during the study.\n21. Subject having received within the past 18 months or planning to receive during the study any injections outside of those in the study protocol including non-permanent fillers (e.g., HA, Calcium Hydroxyapatite) or autologous fat on or near the face.\n22. Subject having received within the past 9 months or planning to receive during the study any injections outside of those in the study protocol including mesotherapy or botulinum neurotoxin on or near the face.\n23. Subject having received at any time or planning to receive a permanent filler on the face (e.g., polylactic acid, Polymethylmethacrylate, silicone) during the study.\n24. Subject with subcutaneous retaining structure on the face (meshing, threads, gold strand).\n25. Subject having received in the last 24 months resorbable threads lift on the face.\n26. Subject having received at any time injection with unknown products\n27. Subject using medication such as aspirin, high dose Vitamin C, nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet agents, thrombolytics or anticoagulants within one week prior to injection visit or being a chronic user.\n28. Subject using medication such as narcotic, and immunosuppressive drugs from three weeks before screening visit and during the whole study period\n29. Subject having started or stopped an antidepressant 3 weeks prior the study or plans to use it during the study.\n30. Subject undergoing a topical treatment on the face or a systemic treatment:\n\n    * anti-inflammatory medication and\u002For antihistamines within the past 2 weeks and during the study,\n    * corticosteroids within the past 2 weeks and during the study,\n    * retinoids and\u002For immunosuppressors within the past 3 months and during the study.\n\n    In terms of lifestyle\n31. Intensive exposure to sunlight or UV-rays within the previous month and\u002For planning to do so during the study.\n32. Heavy smoker (subject who reports smoking 10 or more cigarettes per day);\n33. Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day)","55 Years",{"count":298,"type":22},164,"Profhilo® Structura is composed of a buffered saline solution of high molecular weight (H-HA) and low molecular weight (L-HA) hyaluronic acid. The high- and low-molecular-weight HA used in the device is obtained by biofermentation and has not undergone chemical modification processes; this results in excellent tolerability of the product.\n\nIn addition, the HA chains with different molecular weight present in Profhilo® Structura, thanks to a specific and patented treatment of the solution (NAHYCO® Hybrid Technology), interact with each other, giving Profhilo® Structura unique rheological properties that allow higher concentrations of HA to be administered at equal viscosity of the solution.\n\nThe formulation based on HA with different molecular weight contained in Profhilo® Structura is based on the Hydrolift® Action system, the innovative approach aimed at combating the physiological decrease of HA in the skin, restoring hydration, elasticity and tone, synergistically associating deep hydration with the mechanical lifting action of the skin depression.\n\nThanks to its rheological properties and cohesivity Profhilo® Structura is able to optimally spread and integrate into the interstitial spaces of the adipose tissue. Profhilo® Structura has the specific indication for adipose tissue restoration and is able to counteract facial volume loss.",[28],[302,303],"aging","adipose tissue","2024-12-02",{"date":306,"type":47},"2024-12-05",{"date":308,"type":47},"2024-09-09",{"date":310,"type":22},"2025-12",{"name":312,"class":54},"IBSA Farmaceutici Italia Srl",3,{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":16,"sex":63,"minAge":168,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":4},"100565186","phase-2-efficacy-and-safety-of-skincare-serum-and-cream-for-anti-aging-of-facial-skin-100565186","NCT06638905","Efficacy and Safety of Skincare Serum and Cream for Anti-aging of Facial Skin","A Prospective, Open Label Clinical Study Evaluating the Efficacy and Safety of Skincare Serum and Cream for Anti-aging of Facial Skin","Inclusion Criteria:\n\n* Men and women between the ages of 18 and 50 years old (inclusive).\n* Subjects must be able and willing to provide written informed consent and photography release.\n* At the baseline evaluation, all subjects must exhibit mild to moderate skin aging, as defined below (Appendix A):\n\n  1. Class I-II of Wrinkling on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale\n  2. Score 1-6 of Degree of Elastosis on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale\n  3. Mild to Moderate on Redness\u002FErythema Grading Scale\n  4. Mild to Moderate on Dryness\u002FScaling\u002FRoughness Grading Scale\n  5. Mild to Moderate on Luminosity Scale\n* Subject must be in good general health with no other skin disease, disease state or physical condition which would impair evaluation of the areas to be treated or which would increase the subject's health risk by study participation.\n* Subjects must have a willingness to minimize sun exposure, avoid direct sun exposure on the face, and avoid the use of tanning beds for the entire duration of the study. Must be willing to wear a hat and reapply sunscreen if sun exposure is unavoidable.\n* Subjects must be willing and able to understand and comply with the requirements of the study including prolonged sun exposure and apply the products as instructed, return for the required treatment period visits, comply with therapy prohibitions, and be able to complete the study\n* For female subjects of childbearing potential, must be willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.\n\n  1. A female is considered of childbearing potential unless she is postmenopausal, without a uterus and\u002For both ovaries, or has had a bilateral tubal ligation.\n  2. Acceptable methods of birth control are: oral contraceptives, contraceptive patches\u002Frings\u002Fimplants, Implanon®, Depo-Provera®, double-barrier methods (e.g., condoms and spermicide), abstinence, and\u002For vasectomy of partner with a documented second acceptable method of birth control, should the subject become sexually active.\n\nExclusion Criteria:\n\n* Subjects who are pregnant, planning pregnancy during the course of the study, or breastfeeding.\n* Subjects with an active bacterial, fungal, or viral infection in the treatment area\n* Subjects with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.\n* Subjects receiving any topical products containing tretinoins or derivatives, alpha-hydroxy acids, salicylic acid, and vitamins C or E (includes derivatives thereof) on the face within 14 days prior to or during the study period, other than the study products.\n* Subjects receiving a chemical peel, any systemic steroids, a non-ablative laser, ablative laser, microfocused ultrasound, light or radio frequency treatment, deep chemical peel, and\u002For has had a Dermabrasion on their face must have discontinued the drug\u002Ftreatment and\u002For had the procedure at least 6 months prior to entering the study.\n* Subjects who have had a microdermabrasion (light or medium skin peel) treatment on their face within 30 days prior to and not willing to refrain from use for the duration of the study period.\n* Subjects with recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds\u002Fbooths and\u002For sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days of study entry.\n* Subjects that has previously been treated with a systemic retinoid within the past 3 months (e.g., Accutane®, Roche Dermatologics).\n* Subjects with a history of keloids or hypertrophic scars.\n* Subjects with known allergies to any of the product ingredients.\n* Subjects with a tattoo and\u002For scar in the treatment area that in the investigators opinion would interfere with study assessments.\n* Subjects with history of or the presence of any skin condition\u002Fdisease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) at the discretion of the investigator.\n* Inability to comply with all study protocol restrictions and visits.\n* Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.\n* History of non-compliance with clinical research protocols.","50 Years",{"count":323,"type":22},18,[325,199],"PHASE2","The primary objective of this study is to assess the efficacy and safety of combination therapy of BABOR® Ultimate ECM Repair Serum and the BABOR® Cure Cream for the improvement of anti-aging through the use of investigator assessments, subject questionnaires\u002Fassessments, photography, skin imaging, and reported adverse reactions.",[328,28],"Facial Wrinkles",[73,330,331,332],"Face Wrinkles","Cosmetic","Crow's Feet","2024-10-09",{"date":335,"type":47},"2024-10-15",{"date":337,"type":22},"2024-10-28",{"date":339,"type":22},"2025-05-05",{"name":341,"class":93},"Goldman, Butterwick, Fitzpatrick and Groff"]